

Appendix IV


ToxiSENS Data

CJSC: 306-01-02-05

Human PBMCs (Unstimulated) Cytotoxicity: FDA

TOXICITY VALUES (XTT - O. D. @ 450/650 nm)							
CONC (μM)	0	0.32	1	3.16	9.99	31.6	100
SAMPLE 1	2.132	2.011	1.883	1.775	1.464	1.371	1.481
SAMPLE 2	2.046	2.130	2.004	1.678	1.427	1.423	1.350
SAMPLE 3	2.047	2.121	1.981	1.709	1.511	1.451	1.341
MEAN	2.075	2.087	1.956	1.721	1.467	1.415	1.391
% CC	100.0	100.6	94.2	82.9	70.7	68.2	67.0
STD DEV	2.4	3.2	3.1	2.4	2.0	1.9	3.8

TC50 (μM) = >100




CJSC: 306-01-02-05

Human PBMCs (Unstimulated) Cytotoxicity: FPACA

TOXICITY VALUES (XTT - O. D. @ 450/650 nm)							
CONC (μ M)	0	0.32	1	3.16	9.99	31.6	100
SAMPLE 1	1.572	1.697	1.669	1.741	1.659	1.701	1.548
SAMPLE 2	1.605	1.724	1.690	1.614	1.569	1.602	1.487
SAMPLE 3	1.722	1.736	1.745	1.684	1.548	1.466	1.514
MEAN	1.633	1.719	1.701	1.680	1.592	1.590	1.516
% CC	100.0	105.3	104.2	102.9	97.5	97.4	92.9
STD DEV	4.8	1.2	2.4	3.9	3.6	7.2	1.9

TC50 (μ M) = >100




CJSC: 306-01-02-05

Human PBMCs (Unstimulated) Cytotoxicity: staurosporin

TOXICITY VALUES (XTT - O. D. @ 450/650 nm)							
CONC (µM)	0	0.03	0.1	0.32	0.99	3.16	1
SAMPLE 1	2.132	1.267	0.850	0.921	0.749	0.513	0.312
SAMPLE 2	2.046	1.184	0.877	0.861	0.710	0.494	0.313
SAMPLE 3	2.047	1.259	0.866	0.899	0.715	0.506	0.311
MEAN	2.075	1.237	0.864	0.893	0.724	0.504	0.312
% CC	100.0	59.6	41.6	43.1	34.9	24.3	15.0
STD DEV	2.4	2.2	0.7	1.5	1.0	0.5	0.0

TC50 (µM) = 0.067




LY 11/13

CJSC: 306-01-02-05

Human PBMCs (Unstimulated) Cytotoxicity: staurosporin

TOXICITY VALUES (XTT - O. D. @ 450/650 nm)							
CONC (μM)	0	0.03	0.1	0.32	0.99	3.16	1
SAMPLE 1	1.572	1.541	1.309	1.002	0.669	0.415	0.388
SAMPLE 2	1.605	1.335	1.268	0.927	0.715	0.449	0.224
SAMPLE 3	1.722	1.801	1.215	0.854	0.615	0.487	0.215
MEAN	1.633	1.559	1.264	0.928	0.666	0.450	0.276
% CC	100.0	95.5	77.4	56.8	40.8	27.6	16.9
STD DEV	4.8	14.3	2.9	4.5	3.1	2.2	6.0

TC50 (μM) = 0.605




CJSC: 306-01-02-05

Human PBMCs (Stimulated) Cytotoxicity: FDA

TOXICITY VALUES (XTT - O. D. @ 450/650 nm)							
CONC (μM)	0	0.32	1	3.16	9.99	31.6	100
SAMPLE 1	1.740	1.979	1.948	1.843	1.925	1.905	1.899
SAMPLE 2	1.688	2.105	2.063	1.938	1.950	2.071	1.887
SAMPLE 3	1.676	1.910	1.730	1.932	1.935	1.903	1.817
MEAN	1.702	1.998	1.914	1.904	1.937	1.960	1.868
% CC	100.0	117.4	112.5	111.9	113.8	115.2	109.8
STD DEV	2.0	5.8	9.9	3.1	0.8	5.6	2.6

TC50 (μM) = >100




CJSC: 306-01-02-05

Human PBMCs (Stimulated) Cytotoxicity: FPACA

TOXICITY VALUES (XTT - O. D. @ 450/650 nm)							
CONC (µM)	0	0.32	1	3.16	9.99	31.6	100
SAMPLE 1	1.751	1.759	1.902	1.865	1.715	1.775	1.806
SAMPLE 2	1.713	1.881	1.864	1.817	1.755	1.881	1.792
SAMPLE 3	1.695	1.805	1.748	1.801	1.865	1.748	1.813
MEAN	1.720	1.815	1.838	1.828	1.778	1.801	1.804
% CC	100.0	105.6	106.9	106.3	103.4	104.8	104.9
STD DEV	1.7	3.6	4.7	1.9	4.5	4.1	0.6

TC50 (µM) = >100




CJSC: 306-01-02-05

Human PBMCs (Stimulated) Cytotoxicity: Staurosporin

TOXICITY VALUES (XTT - O. D. @ 450/650 nm)							
CONC (μM)	0	0.03	0.1	0.32	0.99	3.16	1
SAMPLE 1	1.740	1.693	1.388	0.822	0.660	0.500	0.357
SAMPLE 2	1.688	1.604	1.317	0.690	0.554	0.473	0.363
SAMPLE 3	1.676	1.542	1.374	0.745	0.528	0.459	0.352
MEAN	1.702	1.613	1.360	0.752	0.581	0.477	0.357
% CC	100.0	94.8	79.9	44.2	34.1	28.0	21.0
STD DEV	2.0	4.4	2.2	3.9	4.1	1.2	0.3

TC50 (μM) = 0.284




CJSC: 306-01-02-05

Human PBMCs (Stimulated) Cytotoxicity: Staurosporin

TOXICITY VALUES (XTT - O. D. @ 450/650 nm)							
CONC (μM)	0	0.03	0.1	0.32	0.99	3.16	1
SAMPLE 1	1.751	1.812	1.721	1.002	0.603	0.415	0.223
SAMPLE 2	1.713	1.814	1.648	0.932	0.569	0.425	0.214
SAMPLE 3	1.695	1.774	1.659	0.998	0.624	0.516	0.305
MEAN	1.720	1.800	1.676	0.977	0.599	0.452	0.247
% CC	100.0	104.7	97.5	56.8	34.8	26.3	14.4
STD DEV	1.7	1.3	2.3	2.3	1.6	3.2	2.9

TC50 (μM) = 0.528




CJSC: 306-01-02-05

Monocyte - Macrophages Cytotoxicity: FDA

TOXICITY VALUES (XTT - O. D. @ 450/650 nm)							
CONC (μM)	0	0.32	1	3.16	9.99	31.6	100
SAMPLE 1	1.843	1.403	1.722	2.094	1.882	1.687	1.654
SAMPLE 2	1.966	1.670	1.740	1.130	1.821	1.841	1.386
SAMPLE 3	1.915	1.698	1.357	1.952	1.641	1.570	1.802
MEAN	1.908	1.590	1.606	1.725	1.781	1.699	1.614
% CC	100.0	83.3	84.2	90.4	93.4	89.1	84.6
STD DEV	3.2	8.5	11.3	27.3	6.6	7.1	11.1

TC50 (μM) = >100




CJSC: 306-01-02-05

Monocyte - Macrophages Cytotoxicity: FPACA

TOXICITY VALUES (XTT - O. D. @ 450/650 nm)							
CONC (µM)	0	0.32	1	3.16	9.99	31.6	100
SAMPLE 1	1.743	1.821	1.729	1.699	1.743	1.694	1.458
SAMPLE 2	1.825	1.845	1.764	1.714	1.749	1.728	1.369
SAMPLE 3	1.919	1.716	1.806	1.813	1.755	1.800	1.517
MEAN	1.829	1.794	1.766	1.742	1.749	1.741	1.448
% CC	100.0	98.1	96.6	95.3	95.6	95.2	79.2
STD DEV	4.8	3.8	2.1	3.4	0.3	3.0	4.1

TC50 (µM) = >100




CJSC: 306-01-02-05

Monocyte - Macrophages Cytotoxicity: Staurosporin

TOXICITY VALUES (XTT - O. D. @ 450/650 nm)							
CONC (μM)	0	0.003	0.01	0.03	0.1	0.32	1
SAMPLE 1	1.843	1.354	0.934	1.102	0.462	0.216	0.187
SAMPLE 2	1.966	1.320	1.090	1.327	0.655	0.342	0.180
SAMPLE 3	1.915	1.358	0.952	0.918	0.667	0.228	0.191
MEAN	1.908	1.344	0.992	1.116	0.595	0.262	0.186
% CC	100.0	70.4	52.0	58.5	31.2	13.7	9.7
STD DEV	3.2	1.1	4.5	10.7	6.0	3.6	0.3

TC50 (μM) = 0.052




CJSC: 306-01-02-05

Monocyte - Macrophages Cytotoxicity: Staurosporin

TOXICITY VALUES (XTT - O. D. @ 450/650 nm)							
CONC (μM)	0	0.003	0.01	0.03	0.1	0.32	1
SAMPLE 1	1.743	1.652	1.412	1.036	0.632	0.214	0.263
SAMPLE 2	1.825	1.548	1.009	0.857	0.715	0.305	0.229
SAMPLE 3	1.919	1.608	1.114	0.824	0.659	0.415	0.208
MEAN	1.829	1.603	1.178	0.906	0.669	0.311	0.233
% CC	100.0	87.6	64.4	49.5	36.6	17.0	12.8
STD DEV	4.8	2.9	11.4	6.2	2.3	5.5	1.5

TC50 (μM) = 0.029




CJSC: 306-01-02-05

Dendritic Cells Cytotoxicity: FDA

TOXICITY VALUES (XTT - O. D. @ 450/650 nm)							
CONC (μM)	0	0.32	1	3.16	9.99	31.6	100
SAMPLE 1	1.140	1.229	1.249	1.368	1.252	1.250	1.296
SAMPLE 2	1.184	1.292	1.199	1.442	1.453	1.228	1.169
SAMPLE 3	1.372	1.304	1.509	1.127	1.118	1.370	1.193
MEAN	1.232	1.275	1.319	1.313	1.274	1.282	1.219
% CC	100.0	103.5	107.1	106.5	103.4	104.1	99.0
STD DEV	10.0	3.3	13.5	13.4	13.7	6.2	5.5

TC50 (μM) = >100




LX/11/4/13

CJSC: 306-01-02-05

Dendritic Cells Cytotoxicity: FPACA

TOXICITY VALUES (XTT - O. D. @ 450/650 nm)							
CONC (µM)	0	0.32	1	3.16	9.99	31.6	100
SAMPLE 1	1.171	1.205	1.223	1.198	1.147	1.126	1.113
SAMPLE 2	1.187	1.159	1.216	1.175	1.201	1.154	1.159
SAMPLE 3	1.178	1.215	1.174	1.214	1.182	1.129	1.144
MEAN	1.179	1.193	1.204	1.196	1.177	1.136	1.139
% CC	100.0	101.2	102.2	101.5	99.8	96.4	96.6
STD DEV	0.7	2.5	2.2	1.7	2.3	1.3	2.0

TC50 (µM) = >100




CJSC: 306-01-02-05

Dendritic Cells Cytotoxicity: Staurosporin

TOXICITY VALUES (XTT - O. D. @ 450/650 nm)							
CONC (µM)	0	0.003	0.01	0.03	0.1	0.32	1
SAMPLE 1	1.140	1.227	1.108	1.121	0.728	0.517	0.335
SAMPLE 2	1.184	1.287	1.182	1.137	0.768	0.581	0.363
SAMPLE 3	1.372	1.322	1.142	1.092	0.783	0.541	0.353
MEAN	1.232	1.279	1.144	1.117	0.760	0.546	0.350
% CC	100.0	103.8	92.9	90.6	61.7	44.3	28.4
STD DEV	10.0	3.9	3.0	1.8	2.3	2.6	1.1

TC50 (µM) = 0.248




CJSC: 306-01-02-05

Dendritic Cells Cytotoxicity: Staurosporin

TOXICITY VALUES (XTT - O. D. @ 450/650 nm)							
CONC (μM)	0	0.003	0.01	0.03	0.1	0.32	1
SAMPLE 1	1.171	1.351	1.597	1.326	1.006	0.615	0.348
SAMPLE 2	1.187	1.259	1.228	1.054	1.025	0.489	0.269
SAMPLE 3	1.178	1.315	1.326	1.128	0.948	0.512	0.326
MEAN	1.179	1.308	1.384	1.169	0.993	0.539	0.314
% CC	100.0	111.0	117.4	99.2	84.3	45.7	26.7
STD DEV	0.7	3.9	16.2	11.9	3.4	5.7	3.5

TC50 (μM) = 0.296




Evaluation of Bone Marrow Toxicity by AZT

GM-CFU Assay

CFU/10 ⁵ cells (Day 14)							
CONC (μM)	0	0.032	0.1	0.32	1	3.2	10
SAMPLE 1	49	35	44	40	23	6	1
SAMPLE 2	66	58	53	32	15	4	1
SAMPLE 3	43	50	31	37	9	2	2
MEAN	53	48	43	36	16	4	1
% CC	100.0	90.5	81.0	69.0	29.7	7.6	2.5

TC50 (μM) = 0.65




Evaluation of Bone Marrow Toxicity by AZT

GM-CFU Assay

CFU/10 ⁵ cells (Day 14)							
CONC (μM)	0	0.032	0.1	0.32	1	3.2	10
SAMPLE 1	55	49	37	23	12	3	2
SAMPLE 2	41	36	30	18	8	2	2
SAMPLE 3	37	44	42	29	13	1	2
MEAN	44	43	36	23	11	2	2
% CC	100.0	97.0	82.0	52.6	24.8	4.5	4.5


TC50 (μM) = 0.38



Evaluation of Bone Marrow Toxicity by Fullerene Poly-Aminocaproic Acid GM-CFU Assay

CFU/10 ⁵ cells (Day 14)							
CONC (µg/mL)	0	0.32	1	0.2	10	32	100
SAMPLE 1	49	56	51	48	64	47	46
SAMPLE 2	66	48	62	50	43	59	52
SAMPLE 3	43	55	49	61	45	55	66
MEAN	53	53	54	53	51	54	55
% CC	100.0	100.6	102.5	100.6	96.2	101.9	103.8

TC50 (µg/mL) = >100




CJSC Intelpharm: 306-01-02-05

Fresh Human Hepatocyte Cytotoxicity: : Staurosporine

TOXICITY VALUES (XTT - O. D. @ 450/650 nm)							
CONC (μM)	0	0.032	0.1	0.32	1	3.2	10
SAMPLE 1	1.009	0.801	1.040	0.879	0.401	0.241	0.158
SAMPLE 2	0.806	0.936	0.973	0.819	0.298	0.167	0.122
SAMPLE 3	0.937	0.914	1.074	1.044	0.759	0.258	0.133
MEAN	0.917	0.884	1.029	0.914	0.486	0.222	0.138
% CC	100.0	96.3	112.2	99.6	53.0	24.2	15.0
STD DEV	11.2	7.9	5.6	12.7	26.4	5.3	2.0

TC50 (μM) = 1.23




CJSC Intelpharm: 306-01-02-05

Fresh Human Hepatocyte Cytotoxicity: : Staurosporine

TOXICITY VALUES (XTT - O. D. @ 450/650 nm)							
CONC (µM)	0	0.032	0.1	0.32	1	3.2	10
SAMPLE 1	1.036	1.003	1.005	0.659	0.395	0.137	0.125
SAMPLE 2	1.001	1.115	1.128	0.774	0.551	0.118	0.139
SAMPLE 3	0.954	1.068	1.098	0.627	0.412	0.214	0.204
MEAN	0.997	1.062	1.077	0.687	0.453	0.156	0.156
% CC	100.0	106.5	108.0	68.9	45.4	15.7	15.6
STD DEV	4.1	5.6	6.4	7.8	8.6	5.1	4.2

TC50 (µM) = 0.87




CJSC Intelpharm: 306-01-02-05

Fresh Human Hepatocyte Cytotoxicity: Fullerene Poly-A-Aminocaproic Acid

TOXICITY VALUES (XTT - O. D. @ 450/650 nm)							
CONC (µg/mL)	0	0.32	1	3.2	10	32	100
SAMPLE 1	1.009	0.919	1.078	1.055	1.076	1.027	1.092
SAMPLE 2	0.806	0.957	0.894	1.043	1.044	1.058	1.036
SAMPLE 3	0.937	0.983	1.102	1.055	1.058	1.031	1.085
MEAN	0.917	0.953	1.025	1.051	1.059	1.039	1.071
% CC	100.0	103.9	111.7	114.6	115.5	113.2	116.8
STD DEV	11.2	3.5	12.4	0.8	1.7	1.8	3.3

TC50 (µg/mL) = >100




CJSC Intelpharm: 306-01-02-05

Fresh Human Hepatocyte Cytotoxicity: Fullerene PAA

TOXICITY VALUES (XTT - O. D. @ 450/650 nm)							
CONC (µg/mL)	0	0.32	1	3.2	10	32	100
SAMPLE 1	1.036	0.996	1.036	1.062	1.066	1.023	1.049
SAMPLE 2	1.001	1.066	1.074	1.089	1.046	1.038	1.027
SAMPLE 3	0.954	1.083	1.049	1.038	1.029	1.029	1.017
MEAN	0.997	1.048	1.053	1.063	1.047	1.030	1.031
% CC	100.0	105.1	105.6	106.6	105.0	103.3	103.4
STD DEV	4.1	4.6	1.9	2.6	1.9	0.8	1.6

TC50 (µg/mL) = >100




CJSC Intelpharm: 306-01-02-05

iPS Human Cardiomyocytes Cytotoxicity: Doxazosin mesylate

TOXICITY VALUES (XTT - O. D. @ 450/650 nm)							
CONC (μM)	0	0.32	1	3.2	10	32	100
SAMPLE 1	1.832	1.728	1.642	1.441	1.613	1.547	0.201
SAMPLE 2	1.947	1.872	1.728	1.714	1.878	1.644	0.221
SAMPLE 3	1.975	2.073	1.899	2.020	2.199	1.694	0.234
MEAN	1.918	1.891	1.756	1.725	1.897	1.628	0.219
% CC	100.0	98.6	91.6	89.9	98.9	84.9	11.4
STD DEV	4.0	9.0	6.8	15.1	15.3	3.9	0.9

TC50 (μM) = 64.29




CJSC Intelpharm: 306-01-02-05

iPS Human Cardiomyocytes Cytotoxicity: Doxazosin mesylate

TOXICITY VALUES (XTT - O. D. @ 450/650 nm)							
CONC (μM)	0	0.32	1	3.2	10	32	100
SAMPLE 1	1.736	1.739	1.735	1.715	1.725	1.223	0.187
SAMPLE 2	1.801	1.758	1.802	1.665	1.698	1.318	0.202
SAMPLE 3	1.719	1.777	1.784	1.711	1.732	1.284	0.194
MEAN	1.752	1.758	1.774	1.697	1.718	1.275	0.194
% CC	100.0	100.3	101.2	96.9	98.1	72.8	11.1
STD DEV	2.5	1.1	2.0	1.6	1.0	2.7	0.4

TC50 (μM) = 57.11




CJSC Intelpharm: 306-01-02-05

iPS Human Cardiomyocytes Cytotoxicity : Fullerene Poly-A-Aminocaproic Acid

TOXICITY VALUES (XTT - O. D. @ 450/650 nm)							
CONC (µg/mL)	0	0.32	1	3.2	10	32	100
SAMPLE 1	1.832	1.871	1.794	1.784	2.011	1.873	1.631
SAMPLE 2	1.947	1.801	2.077	2.120	2.139	1.731	1.885
SAMPLE 3	1.975	1.848	1.947	1.949	1.969	1.758	1.785
MEAN	1.918	1.840	1.939	1.951	2.040	1.787	1.767
% CC	100.0	95.9	101.1	101.7	106.3	93.2	92.1
STD DEV	4.0	1.9	7.4	8.8	4.6	3.9	6.7

TC50 (µg/mL) = >100




CJSC Intelpharm: 306-01-02-05

iPS Human Cardiomyocytes Cytotoxicity: : Fullerene Poly-A-Aminocaproic Acid

TOXICITY VALUES (XTT - O. D. @ 450/650 nm)							
CONC (µg/mL)	0	0.32	1	3.2	10	32	100
SAMPLE 1	1.736	1.659	1.729	1.719	1.814	1.743	1.644
SAMPLE 2	1.801	1.778	1.742	1.803	1.759	1.751	1.705
SAMPLE 3	1.719	1.794	1.662	1.699	1.732	1.769	1.748
MEAN	1.752	1.744	1.711	1.740	1.768	1.754	1.699
% CC	100.0	99.5	97.7	99.3	100.9	100.1	97.0
STD DEV	2.5	4.2	2.5	3.1	2.4	0.8	3.0

TC50 (µg/mL) = >100




CJSC Intelpharm: 306-01-02-05

iPS Human Neurons Cytotoxicity: Staurosporine

TOXICITY VALUES (XTT - O. D. @ 450/650 nm)							
CONC (μM)	0	0.032	0.1	0.32	1	3.2	10
SAMPLE 1	1.304	1.230	1.236	1.011	0.217	0.187	0.172
SAMPLE 2	1.281	1.249	1.250	1.017	0.226	0.191	0.176
SAMPLE 3	1.298	1.280	1.262	1.029	0.235	0.201	0.168
MEAN	1.294	1.253	1.249	1.019	0.226	0.193	0.172
% CC	100.0	96.8	96.5	78.7	17.5	14.9	13.3
STD DEV	0.9	1.9	1.0	0.7	0.7	0.6	0.3

TC50 (μM) = 0.64




CJSC Intelpharm: 306-01-02-05

iPS Human Neurons Cytotoxicity: Staurosporine

TOXICITY VALUES (XTT - O. D. @ 450/650 nm)							
CONC (μM)	0	0.032	0.1	0.32	1	3.2	10
SAMPLE 1	1.215	1.223	1.218	0.854	0.354	0.201	0.157
SAMPLE 2	1.296	1.248	1.239	1.002	0.451	0.228	0.187
SAMPLE 3	1.235	1.294	1.264	0.924	0.398	0.218	0.194
MEAN	1.249	1.255	1.240	0.927	0.401	0.216	0.179
% CC	100.0	100.5	99.3	74.2	32.1	17.3	14.4
STD DEV	3.4	2.9	1.8	5.9	3.9	1.1	1.6

TC50 (μM) = 0.71




CJSC Intelpharm: 306-01-02-05

iPS Human Neurons Cytotoxicity: : Fullerene Poly-A-Aminocaproic Acid

TOXICITY VALUES (XTT - O. D. @ 450/650 nm)							
CONC (µg/mL)	0	0.32	1	3.2	10	32	100
SAMPLE 1	1.304	1.305	1.306	1.319	1.308	1.388	1.390
SAMPLE 2	1.281	1.306	1.329	1.285	1.309	1.341	1.341
SAMPLE 3	1.298	1.237	1.377	1.382	1.381	1.347	1.393
MEAN	1.294	1.283	1.337	1.329	1.333	1.359	1.375
% CC	100.0	99.1	103.3	102.7	103.0	105.0	106.2
STD DEV	0.9	3.1	2.8	3.8	3.2	2.0	2.3

TC50 (µg/mL) = >100




CJSC Intelpharm: 306-01-02-05

iPS Human Neurons Cytotoxicity: : Fullerene Poly-A-Aminocaproic Acid

TOXICITY VALUES (XTT - O. D. @ 450/650 nm)							
CONC (µg/mL)	0	0.32	1	3.2	10	32	100
SAMPLE 1	1.215	1.268	1.301	1.257	1.224	1.306	1.298
SAMPLE 2	1.296	1.241	1.305	1.287	1.239	1.271	1.301
SAMPLE 3	1.235	1.248	1.254	1.269	1.244	1.237	1.248
MEAN	1.249	1.252	1.287	1.271	1.236	1.271	1.282
% CC	100.0	100.3	103.0	101.8	99.0	101.8	102.7
STD DEV	3.4	1.1	2.3	1.2	0.8	2.8	2.4

TC50 (µg/mL) = >100




CJSC Intelpharm: 306-01-02-05

Human Primary Renal Proximal Tubule (RPTEC) Cytotoxicity: Cisplatin

TOXICITY VALUES (XTT - O. D. @ 450/650 nm)							
CONC (μM)	0	0.000032	0.0001	0.0032	0.001	0.032	0.01
SAMPLE 1	1.314	1.272	1.346	1.268	0.539	0.163	0.168
SAMPLE 2	1.291	1.378	1.310	1.287	0.518	0.166	0.169
SAMPLE 3	1.304	1.328	1.306	1.284	0.462	0.164	0.165
MEAN	1.303	1.326	1.321	1.280	0.506	0.164	0.167
% CC	100.0	101.8	101.4	98.2	38.9	12.6	12.8
STD DEV	0.9	4.1	1.7	0.8	3.1	0.1	0.2

TC50 (μM) = 0.001




CJSC Intelpharm: 306-01-02-05

Human Primary Renal Proximal Tubule (RPTEC) Cytotoxicity: Cisplatin

TOXICITY VALUES (XTT - O. D. @ 450/650 nm)							
CONC (μM)	0	0.000032	0.0001	0.0032	0.001	0.032	0.01
SAMPLE 1	1.329	1.384	1.298	1.204	0.684	0.205	0.157
SAMPLE 2	1.225	1.326	1.354	1.284	0.354	0.198	0.185
SAMPLE 3	1.314	1.347	1.361	1.115	0.571	0.234	0.169
MEAN	1.289	1.352	1.338	1.201	0.536	0.212	0.170
% CC	100.0	104.9	103.7	93.1	41.6	16.5	13.2
STD DEV	4.4	2.3	2.7	6.6	13.0	1.5	1.1

TC50 (μM) = 0.001




CJSC Intelpharm: 306-01-02-05

Human Primary Renal Proximal Tubule (RPTEC) Cytotoxicity: Fullerene Poly-A-Aminocaproic Acid

TOXICITY VALUES (XTT - O. D. @ 450/650 nm)							
CONC (µg/mL)	0	0.32	1	3.2	10	32	100
SAMPLE 1	1.296	1.279	1.260	1.259	1.268	1.246	1.044
SAMPLE 2	1.352	1.233	1.136	1.268	1.210	1.196	0.993
SAMPLE 3	1.262	1.261	1.225	1.214	1.237	1.068	0.976
MEAN	1.303	1.258	1.207	1.247	1.238	1.170	1.004
% CC	100.0	96.5	92.6	95.7	95.0	89.8	77.1
STD DEV	3.5	1.8	4.9	2.2	2.2	7.0	2.7

TC50 (µg/mL) = >100




CJSC Intelpharm: 306-01-02-05

Human Primary Renal Proximal Tubule (RPTEC) Cytotoxicity: Fullerene PAA

TOXICITY VALUES (XTT - O. D. @ 450/650 nm)							
CONC (µg/mL)	0	0.32	1	3.2	10	32	100
SAMPLE 1	1.329	1.300	1.247	1.214	1.254	1.315	1.274
SAMPLE 2	1.225	1.293	1.230	1.238	1.304	1.306	1.218
SAMPLE 3	1.314	1.247	1.267	1.269	1.267	1.269	1.277
MEAN	1.289	1.280	1.248	1.240	1.275	1.297	1.256
% CC	100.0	99.3	96.8	96.2	98.9	100.6	97.4
STD DEV	4.4	2.2	1.4	2.1	2.0	1.9	2.6

TC50 (µg/mL) = >100




CJSC Intelpharma: SOW306-01-02-05

Apoptosis of HeLa Cells: Staurosporine

FLUORESCENCE VALUES (485/530 nm)							
CONC (μM)	0	0.032	0.1	0.32	1	3.2	10
SAMPLE 1	2209	1121	638	343	205	273	311
SAMPLE 2	2139	1126	987	383	210	308	297
SAMPLE 3	2620	1323	956	411	277	289	321
MEAN	2323	1190	860	379	231	290	310
% CC	100.0	51.2	37.0	16.3	9.9	12.5	13.3
STD DEV	11.2	5.0	8.3	1.5	1.7	0.8	0.5

ED_{50} (μM) = 0.04




CJSC Intelpharma: SOW306-01-02-05

Apoptosis of HeLa Cells: Staurosporine

FLUORESCENCE VALUES (485/530 nm)							
CONC (μM)	0	0.032	0.1	0.32	1	3.2	10
SAMPLE 1	2015	1587	1251	854	312	365	273
SAMPLE 2	2384	1624	1002	721	335	301	299
SAMPLE 3	2441	1938	1204	794	401	289	247
MEAN	2280	1716	1152	790	349	318	273
% CC	100.0	75.3	50.5	34.6	15.3	14.0	12.0
STD DEV	10.1	8.5	5.8	2.9	2.0	1.8	1.1

ED_{50} (μM) = 0.11




CJSC Intelpharma: SOW306-01-02-05

Apoptosis of HeLa Cells: Fullerene Poly-Aminocaproic Acid

FLUORESCENCE VALUES (485/530 nm)							
CONC (µg/mL)	0	0.32	1	3.2	10	32	100
SAMPLE 1	2209	2295	3025	3894	4756	4856	5163
SAMPLE 2	2139	2470	3042	3462	3815	4238	5159
SAMPLE 3	2620	2303	2963	3082	4221	3452	5253
MEAN	2323	2356	3010	3479	4264	4182	5192
% CC	100.0	101.4	129.6	149.8	183.6	180.1	223.5
STD DEV	11.2	4.3	1.8	17.5	20.3	30.3	2.3

ED₅₀ (µg/mL) = >100




CJSC Intelpharma: SOW306-01-02-05

Apoptosis of HeLa Cells: FPACA

FLUORESCENCE VALUES (485/530 nm)							
CONC (µg/mL)	0	0.32	1	3.2	10	32	100
SAMPLE 1	2015	1797	1976	2269	3240	4126	4475
SAMPLE 2	2384	1718	1866	2329	2703	3014	4874
SAMPLE 3	2441	2245	2144	2417	2771	4162	4171
MEAN	2280	1920	1995	2338	2905	3767	4507
% CC	100.0	84.2	87.5	102.6	127.4	165.2	197.7
STD DEV	10.1	12.5	6.1	3.3	12.8	28.6	15.5

ED₅₀ (µg/mL) = >100




CJSC Intelpharm: 306-01-02-05

Membrane Integrity Evaluation of L929 Cells: TNF α

FLUORESCENCE VALUES (560/590 nm)							
CONC (ng/mL)	0	0.1	0.01	0.032	0.1	0.32	1
SAMPLE 1	832	748	711	688	3095	3260	4029
SAMPLE 2	973	732	738	685	2572	4014	4121
SAMPLE 3	886	751	726	793	3581	3899	4075
MEAN	897	744	725	722	3083	3724	4075
% CC	24.0	19.9	19.4	19.3	82.5	99.7	109.0
STD DEV	7.9	1.1	1.5	6.9	56.3	45.3	5.1

ED₅₀ (ng/mL) = 0.07




CJSC Intelpharm: 306-01-02-05

Membrane Integrity Evaluation of L929 Cells: TNF α

FLUORESCENCE VALUES (560/590 nm)							
CONC (ng/mL)	0	0.1	0.01	0.032	0.1	0.32	1
SAMPLE 1	812	854	736	815	2215	3594	3878
SAMPLE 2	903	882	778	840	2013	3214	3941
SAMPLE 3	847	902	751	748	1958	2845	3984
MEAN	854	879	755	801	2062	3218	3934
% CC	22.9	23.5	20.2	21.4	55.2	86.1	105.3
STD DEV	5.4	2.8	2.5	5.6	15.8	43.9	6.2

ED₅₀ (ng/mL) = 0.04




CJSC Intelpharm: 306-01-02-05

Membrane Integrity Evaluation of L929 Cells: Fullerene Poly-Aminocaproic Acid

FLUORESCENCE VALUES (560/590 nm)							
CONC (µg/mL)	0	0.32	1	3.2	10	32	100
SAMPLE 1	740	927	789	790	780	733	784
SAMPLE 2	833	824	904	777	768	773	721
SAMPLE 3	803	800	889	752	744	755	720
MEAN	792	850	861	773	764	754	742
% CC	21.2	22.8	23.0	20.7	20.4	20.2	19.8
STD DEV	6.0	8.5	7.9	2.4	2.3	2.5	4.6

ED_{50} (µg/mL) = >100




CJSC Intelpharm: 306-01-02-05

Membrane Integrity Evaluation of L929 Cells: FPACA

FLUORESCENCE VALUES (560/590 nm)							
CONC (µg/mL)	0	0.32	1	3.2	10	32	100
SAMPLE 1	812	819	869	765	744	757	718
SAMPLE 2	903	856	925	767	761	793	707
SAMPLE 3	847	831	862	770	740	802	795
MEAN	854	835	885	767	748	784	740
% CC	22.9	22.4	23.7	20.5	20.0	21.0	19.8
STD DEV	5.4	2.2	4.0	0.3	1.3	2.8	5.6

ED₅₀ (µg/mL) = >100



CJSC Intelpharm: 306-01-02-05


Cellular Proliferation Evaluation of Fresh Human PBMCs (+/- PHA Stimulation): Doxorubicin

BrdU ELISA (450/550 nm) - No PHA Stimulation							
CONC (µM)	0	0.32	1	3.2	10	32	100
SAMPLE 1	0.995	1.022	1.251	0.561	0.205	0.199	0.046
SAMPLE 2	0.736	1.365	1.218	0.400	0.318	0.153	0.066
SAMPLE 3	0.741	1.091	0.941	0.514	0.241	0.185	0.085
MEAN	0.824	1.159	1.137	0.492	0.255	0.179	0.066
% CC	100.0	140.7	137.9	59.7	30.9	21.7	8.0
STD DEV	12.2	14.9	14.0	6.8	4.7	1.9	1.6

BrdU ELISA (450/550 nm) - With 10 µg/mL PHA							
CONC (µM)	0	0.32	1	3.2	10	32	100
SAMPLE 1	1.286	1.069	0.832	0.751	0.358	0.100	0.194
SAMPLE 2	1.067	0.898	0.643	0.726	0.646	0.261	0.199
SAMPLE 3	1.298	0.956	0.751	0.735	0.632	0.114	0.139
MEAN	1.217	0.974	0.742	0.737	0.545	0.158	0.177
% CC	100.0	80.1	61.0	60.6	44.8	13.0	14.6
STD DEV	10.7	7.1	7.8	1.0	13.3	7.3	2.7

ED₅₀ (µM) no PHA = 5.49

ED₅₀ (µM) + PHA = 7.76



CJSC Intelpharm: 306-01-02-05


Cellular Proliferation Evaluation of Fresh Human PBMCs (+/- PHA Stimulation): Doxorubicin

BrdU ELISA (450/550 nm) - No PHA Stimulation							
CONC (µM)	0	0.32	1	3.2	10	32	100
SAMPLE 1	1.025	1.125	1.169	0.842	0.326	0.241	0.098
SAMPLE 2	1.113	1.005	1.157	0.874	0.561	0.197	0.102
SAMPLE 3	1.098	1.124	1.069	0.615	0.247	0.169	0.112
MEAN	1.079	1.085	1.132	0.777	0.378	0.202	0.104
% CC	100.0	100.6	104.9	72.0	35.0	18.8	9.6
STD DEV	3.6	5.2	4.1	10.7	12.4	2.8	0.5

BrdU ELISA (450/550 nm) - With 10 µg/mL PHA							
CONC (µM)	0	0.32	1	3.2	10	32	100
SAMPLE 1	1.362	1.354	1.002	0.984	0.652	0.257	0.158
SAMPLE 2	1.295	1.211	1.102	0.857	0.721	0.301	0.184
SAMPLE 3	1.300	1.236	0.925	0.998	0.532	0.225	0.196
MEAN	1.319	1.267	1.010	0.946	0.635	0.261	0.179
% CC	100.0	96.1	76.5	71.7	48.1	19.8	13.6
STD DEV	2.8	5.8	6.7	5.9	7.3	2.9	1.5

ED₅₀ (µM) no PHA = 7.24

ED₅₀ (µM) + PHA = 9.45



CJSC Intelpharm: 306-01-02-05


Cellular Proliferation Evaluation of Fresh Human PBMCs (+/- PHA Stimulation): Fullerene PAA

BrdU ELISA (450/550 nm) - No PHA Stimulation							
CONC (µg/mL)	0	0.32	1	3.2	10	32	100
SAMPLE 1	0.995	0.533	0.799	0.731	0.660	0.805	0.237
SAMPLE 2	0.736	0.730	0.747	0.763	0.510	0.847	0.166
SAMPLE 3	0.741	0.776	0.740	0.751	0.744	0.686	0.172
MEAN	0.824	0.680	0.762	0.748	0.638	0.779	0.192
% CC	100.0	82.5	92.5	90.8	77.4	94.6	23.3
STD DEV	12.2	10.6	2.6	1.3	9.7	6.9	3.2

BrdU ELISA (450/550 nm) - With 10 µg/mL PHA							
CONC (µg/mL)	0	0.32	1	3.2	10	32	100
SAMPLE 1	1.286	1.672	1.311	1.472	0.703	0.531	0.448
SAMPLE 2	1.067	1.962	1.522	1.443	0.699	0.414	0.390
SAMPLE 3	1.298	0.994	0.604	1.043	0.519	0.320	0.260
MEAN	1.217	1.543	1.146	1.319	0.640	0.422	0.366
% CC	100.0	126.8	94.1	108.4	52.6	34.6	30.1
STD DEV	10.7	40.8	39.5	19.7	8.6	8.7	7.9

ED₅₀ (µg/mL) no PHA = 74.5

ED₅₀ (µg/mL) + PHA = 13.2



CJSC Intelpharm: 306-01-02-05


Cellular Proliferation Evaluation of Fresh Human PBMCs (+/- PHA Stimulation): Fullerene PAA

BrdU ELISA (450/550 nm) - No PHA Stimulation							
CONC (µg/mL)	0	0.32	1	3.2	10	32	100
SAMPLE 1	1.025	1.135	1.124	1.006	0.712	0.859	0.439
SAMPLE 2	1.113	1.164	1.169	1.129	0.887	0.814	0.551
SAMPLE 3	1.098	1.127	1.006	1.109	0.985	0.887	0.452
MEAN	1.079	1.142	1.100	1.081	0.861	0.853	0.481
% CC	100.0	105.9	101.9	100.2	79.9	79.1	44.6
STD DEV	3.6	1.5	6.4	5.0	10.5	2.8	4.6

BrdU ELISA (450/550 nm) - With 10 µg/mL PHA							
CONC (µg/mL)	0	0.32	1	3.2	10	32	100
SAMPLE 1	1.362	1.341	1.365	1.248	1.012	0.428	0.325
SAMPLE 2	1.295	1.388	1.301	1.221	1.125	0.559	0.401
SAMPLE 3	1.300	1.326	1.298	0.985	0.874	0.651	0.394
MEAN	1.319	1.352	1.321	1.151	1.004	0.546	0.373
% CC	100.0	102.5	100.2	87.3	76.1	41.4	28.3
STD DEV	2.8	2.5	2.9	11.0	9.5	8.5	3.2

ED₅₀ (µg/mL) no PHA = 89.3

ED₅₀ (µg/mL) + PHA = 26.5




CJSC Intelpharm: 306-01-02-05

Oxidative Stress Evaluation of HeLa Cells: Menadione

LUMINESCENCE VALUES							
CONC (μM)	0	3.2	10	32	100	320	1000
SAMPLE 1	159704	155586	196699	134345	63907	69754	70155
SAMPLE 2	158505	184639	250804	136497	65674	53889	62784
SAMPLE 3	159879	123205	144692	123637	63026	52248	64577
MEAN	159363	154477	197398	131493	64202	58630	65839
% CC	115.6	112.0	143.1	95.4	46.6	42.5	47.7
STD DEV	0.5	19.3	33.3	4.3	0.8	6.1	2.4

ED₅₀ (μM) = 95.3




CJSC Intelpharm: 306-01-02-05

Oxidative Stress Evaluation of HeLa Cells: Menadione

LUMINESCENCE VALUES							
CONC (μM)	0	3.2	10	32	100	320	1000
SAMPLE 1	132568	136651	144262	132457	61214	50021	45871
SAMPLE 2	144251	152248	125874	122548	75847	36971	33356
SAMPLE 3	139847	143298	139874	130021	52484	40251	32659
MEAN	138889	144066	136670	128342	63182	42414	37295
% CC	100.7	104.5	99.1	93.1	45.8	30.8	27.0
STD DEV	4.2	5.6	6.9	3.7	8.5	4.9	5.4

ED_{50} (μM) = 94.0




CJSC Intelpharm: 306-01-02-05

Oxidative Stress Evaluation of HeLa Cells: Fullerene Poly-Aminocaproic Acid

LUMINESCENCE VALUES							
CONC (µg/mL)	0	0.32	1	3.2	10	32	100
SAMPLE 1	122078	152713	120354	151457	143503	147704	167213
SAMPLE 2	167664	155959	123439	133777	154486	154208	172347
SAMPLE 3	158505	116640	126308	161814	159948	146066	159491
MEAN	149416	141771	123367	149016	152646	149326	166350
% CC	108.3	102.8	89.5	108.1	110.7	108.3	120.6
STD DEV	16.1	14.6	2.0	9.5	5.6	2.9	4.3

ED₅₀ (µg/mL) = >100




CJSC Intelpharm: 306-01-02-05

Oxidative Stress Evaluation of HeLa Cells: Fullerene Poly-Aminocaproic Acid

LUMINESCENCE VALUES							
CONC (µg/mL)	0	0.32	1	3.2	10	32	100
SAMPLE 1	132568	145872	140025	136987	130212	140021	132651
SAMPLE 2	144251	133659	132256	130021	135412	139855	138477
SAMPLE 3	139847	152141	143265	135982	142158	130154	142565
MEAN	138889	143891	138515	134330	135927	136677	137898
% CC	100.7	104.3	100.4	97.4	98.6	99.1	100.0
STD DEV	4.2	6.8	4.1	2.7	4.3	4.1	3.6

ED_{50} (µg/mL) = >100




CJSC: 306-01-02-05

Macromolecular Synthesis Evaluation in PBMCs - Tritium Incorporation of Thymidine: FDA

RT COUNTS (CPM)							
CONC (μM)	0	0.32	1	3.16	9.99	31.6	100
SAMPLE 1	80993	76637	72275	78343	73055	67078	52881
SAMPLE 2	82715	84931	70219	63327	67583	60521	46466
SAMPLE 3	82554	80443	76772	69992	60367	60271	49171
MEAN	82087	80670	73089	70554	67002	62623	49506
% CC	100.0	98.3	89.0	86.0	81.6	76.3	60.3
STD DEV	1.2	5.1	4.1	9.2	7.8	4.7	3.9

TC50 (μM) = >100




CJSC: 306-01-02-05

Macromolecular Synthesis Evaluation in PBMCs - Tritium Incorporation of Thymidine: Staurosporin

RT COUNTS (CPM)							
CONC (μM)	0	0.003	0.01	0.03	0.1	0.32	1
SAMPLE 1	80993	65479	29188	2076	1476	1494	1433
SAMPLE 2	82715	65003	32187	1806	1387	1323	1325
SAMPLE 3	82554	66936	29769	1958	1421	1499	1389
MEAN	82087	65806	30381	1947	1428	1439	1382
% CC	100.0	80.2	37.0	2.4	1.7	1.8	1.7
STD DEV	1.2	1.2	1.9	0.2	0.1	0.1	0.1

TC50 (μM) = 0.008




CJSC: 306-01-02-05

Macromolecular Synthesis Evaluation in PBMCs - Tritium Incorporation of Thymidine: Triton X-100

RT COUNTS (CPM)							
CONC (%)	0	0.0003	0.001	0.003	0.01	0.03	0.1
SAMPLE 1	36647	68057	31265	1795	1173	1117	1057
SAMPLE 2	57721	65167	35107	1531	1393	1139	933
SAMPLE 3	73614	68963	38361	1808	1511	1143	1113
MEAN	55994	67396	34911	1711	1359	1133	1034
% CC	100.0	120.4	62.3	3.1	2.4	2.0	1.8
STD DEV	33.1	3.5	6.3	0.3	0.3	0.0	0.2

TC50 (%) = 0.001




LY 11/4/13

CJSC: 306-01-02-05

Macromolecular Synthesis Evaluation in PBMCs - Tritium Incorporation of Leucine: FDA

RT COUNTS (CPM)							
CONC (µM)	0	0.32	1	3.16	9.99	31.6	100
SAMPLE 1	13903	14058	13571	13781	12365	10249	5944
SAMPLE 2	13581	15024	12841	11320	10994	8676	6514
SAMPLE 3	13470	13538	12669	10953	10401	8994	6629
MEAN	13651	14207	13027	12018	11253	9306	6362
% CC	100.0	104.1	95.4	88.0	82.4	68.2	46.6
STD DEV	1.6	5.5	3.5	11.3	7.4	6.1	2.7

TC50 (µM) = 89.241




CJSC: 306-01-02-05

Macromolecular Synthesis Evaluation in PBMCs - Tritium Incorporation of Leucine: Staurosporin

RT COUNTS (CPM)							
CONC (μM)	0	0.03	0.1	0.32	0.99	3.16	1
SAMPLE 1	13903	4385	2175	1263	928	985	1117
SAMPLE 2	13581	4278	2236	1043	1001	1223	1109
SAMPLE 3	13470	4692	2204	1197	1181	1129	790
MEAN	13651	4452	2205	1168	1037	1112	1005
% CC	100.0	32.6	16.2	8.6	7.6	8.1	7.4
STD DEV	1.6	1.6	0.2	0.8	1.0	0.9	1.4

TC50 (μM) = <0.003




LY 11/4/13

CJSC: 306-01-02-05

Macromolecular Synthesis Evaluation in PBMCs - Tritium Incorporation of Leucine: Triton X-100

RT COUNTS (CPM)							
CONC (%)	0	0.0003	0.001	0.003	0.01	0.03	0.1
SAMPLE 1	3719	5134	2400	1191	1131	772	1209
SAMPLE 2	5051	5275	2810	758	981	1245	1305
SAMPLE 3	6234	5149	2978	941	1385	1449	1277
MEAN	5001	5186	2729	963	1166	1155	1264
% CC	100.0	103.7	54.6	19.3	23.3	23.1	25.3
STD DEV	25.2	1.5	5.9	4.3	4.1	6.9	1.0

TC50 (%) = 0.001




LY 11/4/13

CJSC: 306-01-02-05

Macromolecular Synthesis Evaluation in PBMCs - Tritium Incorporation of Uridine: FDA

RT COUNTS (CPM)							
CONC (µM)	0	0.32	1	3.16	9.99	31.6	100
SAMPLE 1	57834	62175	58705	53630	46171	38830	26737
SAMPLE 2	56387	60639	49955	42999	39085	34493	24138
SAMPLE 3	58271	57560	51060	40902	37099	35103	24837
MEAN	57497	60125	53240	45844	40785	36142	25237
% CC	100.0	104.6	92.6	79.7	70.9	62.9	43.9
STD DEV	1.7	4.1	8.3	11.9	8.3	4.1	2.3

TC50 (µM) = 77.976




LY11/4/13

CJSC: 306-01-02-05

Macromolecular Synthesis Evaluation in PBMCs - Tritium Incorporation of Uridine: Staurosporin

RT COUNTS (CPM)							
CONC (μM)	0	0.003	0.01	0.03	0.1	0.32	1
SAMPLE 1	57834	27678	12342	1557	1783	1899	1705
SAMPLE 2	56387	29636	11885	1553	1721	1723	1965
SAMPLE 3	58271	29142	11322	1779	1697	1545	1735
MEAN	57497	28819	11850	1630	1734	1722	1802
% CC	100.0	50.1	20.6	2.8	3.0	3.0	3.1
STD DEV	1.7	1.8	0.9	0.2	0.1	0.3	0.2

TC50 (μM) = 0.003




CJSC: 306-01-02-05

Macromolecular Synthesis Evaluation in PBMCs - Tritium Incorporation of Uridine: Triton X-100

RT COUNTS (CPM)							
CONC (%)	0	0.0003	0.001	0.003	0.01	0.03	0.1
SAMPLE 1	15711	21110	11098	956	1135	1289	1619
SAMPLE 2	25344	20166	8660	1119	1349	1381	1573
SAMPLE 3	31928	24412	9716	1137	1385	1545	1449
MEAN	24328	21896	9825	1071	1290	1405	1547
% CC	100.0	90.0	40.4	4.4	5.3	5.8	6.4
STD DEV	33.5	9.2	5.0	0.4	0.6	0.5	0.4

TC50 (%) = 0.001



LY11/4/13